Abstract：
BACKGROUND: Colorectal cancer is a significant health concern worldwide, with metastatic CRC (mCRC) presenting a particularly challenging prognosis. The FRESCO-2 trial highlighted the potential of fruquintinib in heavily pretreated mCRC patients.
OBJECTIVE: Given the recent changes in drug pricing in China and the evolving mCRC treatments, this study aimed to evaluate the cost-effectiveness of fruquintinib in the context of current Chinese healthcare standards.
METHODS: This study utilized data from the FRESCO-2 trial, incorporating a partitioned-survival model to simulate three health states: Progression-Free Survival, Progressive Disease, and death. Costs and utility values were derived from published literature and the FRESCO-2 trial. Sensitivity analyses were conducted to assess the robustness of the base-case result and to understand the impact of various parameters on the ICER.
RESULTS: The base-case analysis revealed a total cost of $11,089.05 for the fruquintinib group and $5,374.48 for the placebo group. The overall QALYs were higher in the fruquintinib group (0.61 QALYs) compared to the placebo group (0.43 QALYs). The ICER was calculated to be $31,747.67 per QALY. Sensitivity analyses identified the utility of progression-free survival, the cost of fruquintinib, and the costs of best supportive care as significant determinants of ICER.
CONCLUSIONS: Fruquintinib emerges as a promising therapeutic option for refractory mCRC. However, its cost-effectiveness depends on selected willingness-to-pay (WTP) threshold. While the drug\'s ICER surpasses the WTP based on China\'s 2022 GDP per capita, it remains below the threshold set at three times the national GDP.
OBJECTIVE: Given the recent changes in drug pricing in China and the evolving mCRC treatments, this study aimed to evaluate the cost-effectiveness of fruquintinib in the context of current Chinese healthcare standards.
METHODS: This study utilized data from the FRESCO-2 trial, incorporating a partitioned-survival model to simulate three health states: Progression-Free Survival, Progressive Disease, and death. Costs and utility values were derived from published literature and the FRESCO-2 trial. Sensitivity analyses were conducted to assess the robustness of the base-case result and to understand the impact of various parameters on the ICER.
RESULTS: The base-case analysis revealed a total cost of $11,089.05 for the fruquintinib group and $5,374.48 for the placebo group. The overall QALYs were higher in the fruquintinib group (0.61 QALYs) compared to the placebo group (0.43 QALYs). The ICER was calculated to be $31,747.67 per QALY. Sensitivity analyses identified the utility of progression-free survival, the cost of fruquintinib, and the costs of best supportive care as significant determinants of ICER.
CONCLUSIONS: Fruquintinib emerges as a promising therapeutic option for refractory mCRC. However, its cost-effectiveness depends on selected willingness-to-pay (WTP) threshold. While the drug\'s ICER surpasses the WTP based on China\'s 2022 GDP per capita, it remains below the threshold set at three times the national GDP.
摘要：
背景：结直肠癌是全球范围内重大的健康问题，转移性CRC（mCRC）的预后尤其具有挑战性。FRESCO-2试验强调了氟喹替尼在重度预处理的mCRC患者中的潜力。
目的：鉴于中国药品价格的最新变化和不断发展的mCRC治疗方法，这项研究的目的是在当前中国医疗保健标准的背景下评估佛喹替尼的成本-效果.
方法：本研究利用了FRESCO-2试验的数据，结合分区生存模型来模拟三种健康状态：无进展生存，进行性疾病,和死亡。成本和效用值来自已发表的文献和FRESCO-2试验。进行了敏感性分析，以评估基本情况结果的稳健性，并了解各种参数对ICER的影响。
结果：基本案例分析显示，氟喹替尼组的总成本为11,089.05美元，安慰剂组为5,374.48美元。与安慰剂组（0.43QALYs）相比，氟喹替尼组（0.61QALYs）的总体QALYs更高。ICER计算为每QALY31,747.67美元。敏感性分析确定了无进展生存期的效用，fruquintinib的费用，以及最佳支持性护理的成本是ICER的重要决定因素。
结论：Fruquintinib是难治性mCRC的一种有希望的治疗选择。然而,其成本效益取决于选定的支付意愿(WTP)阈值。虽然该药物的ICER超过了基于中国2022年人均GDP的WTP，它仍然低于国家GDP三倍的门槛。
目的：鉴于中国药品价格的最新变化和不断发展的mCRC治疗方法，这项研究的目的是在当前中国医疗保健标准的背景下评估佛喹替尼的成本-效果.
方法：本研究利用了FRESCO-2试验的数据，结合分区生存模型来模拟三种健康状态：无进展生存，进行性疾病,和死亡。成本和效用值来自已发表的文献和FRESCO-2试验。进行了敏感性分析，以评估基本情况结果的稳健性，并了解各种参数对ICER的影响。
结果：基本案例分析显示，氟喹替尼组的总成本为11,089.05美元，安慰剂组为5,374.48美元。与安慰剂组（0.43QALYs）相比，氟喹替尼组（0.61QALYs）的总体QALYs更高。ICER计算为每QALY31,747.67美元。敏感性分析确定了无进展生存期的效用，fruquintinib的费用，以及最佳支持性护理的成本是ICER的重要决定因素。
结论：Fruquintinib是难治性mCRC的一种有希望的治疗选择。然而,其成本效益取决于选定的支付意愿(WTP)阈值。虽然该药物的ICER超过了基于中国2022年人均GDP的WTP，它仍然低于国家GDP三倍的门槛。
